Significantly higher IL-6 production was observed in the AF and NP regions of the E2- and LMHFV-treated groups versus the control (about 1.2 ± 0.06-fold, p < 0.05; Figure 7C). The gene discussed is IL6; the disease is atrial fibrillation.